Lead Product(s) : VMB-100
Therapeutic Area : Urology
Study Phase : Preclinical
Sponsor : Touchlight
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).
Brand Name : VMB-100
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 21, 2023
Lead Product(s) : VMB-100
Therapeutic Area : Urology
Highest Development Status : Preclinical
Sponsor : Touchlight
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VMB-100
Therapeutic Area : Urology
Study Phase : Preclinical
Sponsor : Versameb
Deal Size : Undisclosed
Deal Type : Agreement
Touchlight and Versameb Announce GMP Manufacturing Supply Agreement
Details : The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.
Brand Name : VMB-100
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 01, 2022
Lead Product(s) : VMB-100
Therapeutic Area : Urology
Highest Development Status : Preclinical
Sponsor : Versameb
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Serenoa Repens Extract
Therapeutic Area : Urology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Strum’s findings validate the effectiveness of an LSESr like Valensa’s USPlus® Pure Lipidosterolic Extract of Serenoa repens (LSESr), commonly known as saw palmetto, for improved quality of life in men with lower urinary tract symptoms (LUTS).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2021
Lead Product(s) : Serenoa Repens Extract
Therapeutic Area : Urology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VMB-100
Therapeutic Area : Urology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. VMB-100 shows therapeutic potential in Stress U...
Brand Name : VMB-100
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 04, 2021
Lead Product(s) : VMB-100
Therapeutic Area : Urology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IMB-150
Therapeutic Area : Urology
Study Phase : Preclinical
Sponsor : Imbrium Therapeutics
Deal Size : $59.5 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Imbrium is responsible for all future development activities and funding for LYT-503/IMB-150, for which an IND filing is planned for early 2022.
Brand Name : LYT-503
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 11, 2021
Lead Product(s) : IMB-150
Therapeutic Area : Urology
Highest Development Status : Preclinical
Sponsor : Imbrium Therapeutics
Deal Size : $59.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Oxybutynin,Lidocaine
Therapeutic Area : Urology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The in-vitro and animal data suggest that TRG-100 can safely be used for possible intravesical sustained release of Lidocaine and Oxybutynin in the treatment of BPS/IC.
Brand Name : TRG-100
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 22, 2021
Lead Product(s) : Oxybutynin,Lidocaine
Therapeutic Area : Urology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?